Gregory Enns, MD
Medical Biochemical Genetics · Palo Alto, CANPI 1508961897
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $67,611 of the $88,340 with a category attached, or 76.5%. 10 manufacturers reported payments, led by Travere Therapeutics, Inc. at 33.8% of the total. Reporting peaked in 2020 at $27,028 and has fallen 80.5% since, to $5,275 in 2025.
Across 91 payments — averaging $970.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$30K
- Amgen$20K
- Amicus Therapeutics, Inc.$15K
- Ultragenyx Pharmaceutical Inc.$9K
- Modernatx, Inc.$6K
- UCB SA$5K
- plus $3K from 4 others
Across 298 payments — averaging $3774.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$456K
- PTC Therapeutics, Inc.$426K
- Astellas Pharma Inc$82K
- Saol International Limited$49K
- Takeda Pharmaceuticals U.S.A., Inc.$39K
- Travere Therapeutics, Inc.$30K
- plus $42K from 7 others
What the payments were for
- Consulting fees$67,61177%
- Speaking & faculty fees$19,29422%
- Travel & lodging$8681%
- Food & beverage$3870%
- Education$1800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 40 | $29,838 |
| Amgen | 14 | $20,306 |
| Amicus Therapeutics, Inc. | 17 | $14,798 |
| Ultragenyx Pharmaceutical Inc. | 10 | $8,980 |
| Modernatx, Inc. | 2 | $6,300 |
| UCB SA | 3 | $4,799 |
| Biomarin Pharmaceutical Inc. | 1 | $2,198 |
| Tanabe Pharma America, Inc. | 2 | $880 |
| Mirum Pharmaceuticals, Inc. | 1 | $225 |
| Immedica Pharma US, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (820) Cholbam$27,550
- RAVICTI$20,062
- DOJOLVI$8,800
- POMBILITI$4,023
- OPFOLDA$4,023
- Kuvan$2,198
- Palynziq$2,198
- (815) Thiola$1,500
How this compares
Too few medical biochemical genetics providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical biochemical genetics in Palo Alto
- Annette FeigenbaumSan Diego$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.